From Wikipedia, the free encyclopedia
HIV/AIDS treatment experimental drug
Fipravirimat
|
|
Other names | GSK3640254 |
---|
|
Legal status |
|
---|
|
(1R)-4-[(1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-[2-(1,1-dioxo-1,4-thiazinan-4-yl)ethylamino]-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,11,11b,12,13,13a,13b-tetradecahydrocyclopenta[a]chrysen-9-yl]-1-(fluoromethyl)cyclohex-3-ene-1-carboxylic acid
|
CAS Number | |
---|
PubChem
CID | |
---|
UNII | |
---|
KEGG | |
---|
|
Formula | C43H67FN2O4S |
---|
Molar mass | 727.08 g·mol−1 |
---|
3D model (
JSmol) | |
---|
CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@H]4[C@]([C@@]3(CC2)C)(CC[C@@H]5[C@@]4(CC=C(C5(C)C)C6=CC[C@@](CC6)(CF)C(=O)O)C)C)NCCN7CCS(=O)(=O)CC7
|
InChI=1S/C43H67FN2O4S/c1-29(2)31-12-19-43(45-22-23-46-24-26-51(49,50)27-25-46)21-20-40(6)33(36(31)43)8-9-35-39(5)15-13-32(38(3,4)34(39)14-16-41(35,40)7)30-10-17-42(28-44,18-11-30)37(47)48/h10,13,31,33-36,45H,1,8-9,11-12,14-28H2,2-7H3,(H,47,48)/t31-,33+,34-,35+,36+,39-,40+,41+,42+,43-/m0/s1 Key:YFSNREBZTKMFEB-DHGHKPCRSA-N
|
Fipravirimat is an experimental drug for the treatment of
HIV/AIDS. It belongs to a class of drugs known as
maturation inhibitors.
[1]
[2]
Fipravirimat was being developed by
ViiV Healthcare, but development was stopped in 2023.
[3]
See also
References